X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/innovent-and-anheart-therapeutics-announce-the-nmpa-of-china-has-accepted-second-nda-for-taletrectinib-for-first-line-treatment-of-ros1-positive-lung-cancer-302079359.html
https://www.businesswire.com/news/home/20211025005230/en/AnHeart-Therapeutics-Announces-First-Patient-Dosed-in-Global-Phase-2-TRUST-II-Study-for-Taletrectinib-in-ROS1-Fusion-Positive-Lung-Cancer
https://www.globenewswire.com/news-release/2021/06/18/2249382/0/en/First-Patient-Dosed-in-Phase-II-Basket-Trial-of-Taletrectinib-for-Solid-Tumors-with-NTRK-Fusion.html
https://www.globenewswire.com/news-release/2021/06/18/2249382/0/en/First-Patient-Dosed-in-Phase-II-Basket-Trial-of-Taletrectinib-for-Solid-Tumors-with-NTRK-Fusion.html
https://www.biospace.com/article/releases/anheart-announces-publication-of-pooled-analysis-of-two-phase-1-studies-of-taletrectinib-in-ros1-nsclc/
Market Place
Share 
